gefitinib has been researched along with ldn-212854 in 1 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (ldn-212854) | Trials (ldn-212854) | Recent Studies (post-2010) (ldn-212854) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 12 | 0 | 12 |
Protein | Taxonomy | gefitinib (IC50) | ldn-212854 (IC50) |
---|---|---|---|
Bone morphogenetic protein 4 | Homo sapiens (human) | 0.117 | |
ACVR1 protein | Homo sapiens (human) | 0.026 | |
Bone morphogenetic protein receptor type-1B | Homo sapiens (human) | 0.0929 | |
Bone morphogenetic protein 4 | Mus musculus (house mouse) | 0.117 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 2.04 | |
Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | 0.539 | |
Activin receptor type-1B | Homo sapiens (human) | 4.09 | |
TGF-beta receptor type-1 | Homo sapiens (human) | 3.96 | |
Serine/threonine-protein kinase receptor R3 | Homo sapiens (human) | 0.0144 | |
TGF-beta receptor type-2 | Homo sapiens (human) | 0.327 | |
Activin receptor type-1 | Homo sapiens (human) | 0.0262 | |
Bone morphogenetic protein receptor type-2 | Homo sapiens (human) | 0.695 | |
5'-AMP-activated protein kinase subunit beta-1 | Homo sapiens (human) | 2.52 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB | 1 |
1 other study(ies) available for gefitinib and ldn-212854
Article | Year |
---|---|
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship | 2014 |